Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
All-case post-marketing safety survey of Hiyasta (tucidinostat) in relapsed or refractory peripheral T-cell lymphoma
jRCT2031210606Active, not recruiting
- Sponsor
- Meiji Seika Pharma Co., Ltd.
- Start
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of tucidinostat in peripheral T-cell lymphoma (PTCL), sponsored by Meiji Seika Pharma Co., Ltd. Primary endpoints: Incidence of myelosuppression, Incidence of interstitial lung disease and 2 more. Started Feb 2022; status: active, not recruiting.
02
Drugs
tucidinostat
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on jRCT2031210606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210606.